Voyager Therapeutics, Inc. (VYGR) Stock Price & Analysis
Voyager Therapeutics, Inc. (VYGR) rose 1.78% to USD 3.43 as of June 10, 2026 at 03:36 UTC, according to Nexqual real-time market data.
VYGR last closed at USD 3.37; the session ranged USD 3.31–3.54 on volume of 482,326 shares. Market capitalization is $207.25M, with a 52-week range of USD 2.83–5.55 (NMS). Source: Nexqual, June 10, 2026 at 03:36 UTC.
Key Statistics (as of June 10, 2026 at 03:36 UTC)
| Price | USD 3.43 |
|---|---|
| Change | ▲ 1.78% (up) |
| Previous Close | USD 3.37 |
| Open | USD 3.44 |
| Day Range | USD 3.31 – 3.54 |
| 52-Week Range | USD 2.83 – 5.55 |
| Volume | 482,326 shares |
| Market Cap | $207.25M |
| Exchange | NMS |
Technical Analysis (VYGR)
Nexqual's technical model rates VYGR "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.1 (neutral) |
| vs SMA50 | Below (USD 3.86) |
| MACD | -0.12 (negative) |
Analyst Ratings (VYGR)
Wall Street analysts rate VYGR "Strong Buy" based on 9 analysts, with a mean price target of USD 14.89 (range USD 8–25), per Nexqual as of June 10, 2026 at 03:36 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 14.89 |
| High Target | USD 25 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (VYGR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.52 |
| Revenue Estimate | $4.74M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.47 vs est -0.53 ▲ beat |
| 2025-12-31 | USD -0.47 vs est -0.51 ▲ beat |
| 2025-09-30 | USD -0.47 vs est -0.52 ▲ beat |
| 2025-06-30 | USD -0.57 vs est -0.52 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:36 UTC.
Financials & Fundamentals (VYGR)
| Total Revenue | $36.49M |
|---|---|
| Revenue Growth (YoY) | -59.90% |
| Gross Margin | -243.48% |
| Operating Margin | -1167.37% |
| Profit Margin | +0.00% |
| ROE | -52.26% |
| Debt / Equity | 19.9 |
| Current Ratio | 8.42 |
| Total Cash | $141.48M |
| Total Debt | $34.57M |
| Free Cash Flow | $-80.83M |
Source: Nexqual, June 10, 2026 at 03:36 UTC.
Financial Health Score (VYGR)
Nexqual rates Voyager Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:36 UTC.
| Growth | Critical — Revenue -50% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $141M cash vs $35M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$81M, burning cash |
| Efficiency | Critical — ROE -52%, ROA -27.1% |
Ownership (VYGR)
| Insider Ownership | +15.14% |
|---|---|
| Institutional Ownership | +56.37% |
| Shares Outstanding | 60.42M |
| Float | 44.22M |
| Short % of Float | +7.28% |
Source: Nexqual, June 10, 2026 at 03:36 UTC.
Leadership (VYGR)
Voyager Therapeutics, Inc. is led by Alfred W. Sandrock Jr. (age 67), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:36 UTC.
| President, CEO & Director | Alfred W. Sandrock Jr. (age 67) |
|---|---|
| Principal Financial Officer, Treasurer, Chief Business Officer & COO | Robin Swartz (age 54) |
| Chief Scientific Officer | Todd Carter (age 55) |
| Vice President of Gene Therapy | Mathieu Nonnenmacher |
| Vice President of Non-Viral Therapeutics | Mihalis Kariolis |
Major Backers & Investors (VYGR)
Notable institutional backers of Voyager Therapeutics, Inc. include Armistice Capital, LLC, Millennium Management, Vestal Point Capital, LP, according to Nexqual as of June 10, 2026 at 03:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 5.79% |
| Millennium Management | 5.67% |
| Vestal Point Capital, LP | 4.97% |
| Opaleye Management Inc. | 1.9% |
| Erste Asset Management GmbH | 1.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.3% |
| Vanguard Group | 8.59% |
| Geode Capital | 1.74% |
| State Street | 1.57% |
| Dimensional Fund Advisors | 1.45% |
Source: Nexqual, June 10, 2026 at 03:36 UTC.
From Voyager Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
- Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
- The company also provides research program for the treatment of Huntington's disease.
- In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGNX | REGENXBIO Inc. | USD 6.34 | ▲ 4.28% |
| SLDB | Solid Biosciences Inc. | USD 6.57 | ▼ 1.94% |
| QURE | uniQure N.V. | USD 26.46 | ▲ 0.04% |
| MGTX | MeiraGTx Holdings plc | USD 9.21 | ▲ 2.33% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:36 UTC. This page is informational and not investment advice.